Try our beta test site
4 studies found for:    encorafenib OR lgx818 | Open Studies
Show Display Options
Rank Status Study
1 Recruiting BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Conditions: Relapsed or Refractory Multiple Myeloma;   Patients With BRAFV600 E or BRAFV600K Mutation
Interventions: Drug: Encorafenib;   Drug: Binimetinib
2 Recruiting Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition: BRAF V600E-mutant Metastatic Colorectal Cancer
Interventions: Drug: Encorafenib;   Drug: Binimetinib;   Drug: Cetuximab;   Drug: Irinotecan;   Drug: Folinic Acid;   Drug: 5-Fluorouracil
3 Not yet recruiting Open Label, Multicentre Study of Encorafenib + Binimetinib + PD (Programmed Cell Death Protein) -1 Antibody Pembrolizumab
Condition: Malignant Melanoma
Interventions: Drug: Encorafenib;   Drug: Binimetinib;   Drug: Pembrolizumab;   Drug: Pembrolizumab alone
4 Recruiting Sequential Combo Immuno and Target Therapy (SECOMBIT) Study
Condition: Metastatic Melanoma
Interventions: Drug: LGX818;   Drug: MEK162;   Drug: Nivolumab;   Drug: Ipilimumab

Study has passed its completion date and status has not been verified in more than two years.